177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
Mené sur 468 patients atteints d'un cancer de la prostate résistant à la castration et de stade métastatique, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression mesurée par radiographie, et la toxicité du 177Lu-PSMA-617, après l'échec d'un traitement par inhibiteur des récepteurs des androgènes
Metastatic prostate cancer remains a deadly disease, but advances in clinical and translational research have considerably improved patient prognosis. Beyond androgen receptor-directed therapies (androgen deprivation and androgen receptor pathway inhibitors [ARPIs]), the cornerstone of systemic treatment, recent years have seen treatment options expand to include biomarker-directed targeted therapies, such as poly(ADP-ribose) polymerase (PARP) inhibitors and pembrolizumab, along with taxane-based chemotherapies and 223Ra.1 However, more options bring new challenges, such as determining how to optimally sequence and combine treatments throughout the disease course and ascertaining the best treatment for each patient.